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Although pathogenesis of IgA nephropathy (IgAN) is still obscure, pathological contribution of mucosal immunity including
production of nephritogenic IgA and IgA immune complex (IC) has been discussed. We have reported that mucosal toll-like
receptor (TLR)-9 is involved in the pathogenesis of human and murine IgAN. However, cell-type expressing TLR9 in mucosa
remains unclear. To address this, we nasally challenged cell-speciﬁc CpG DNA ((i): dendritic cell: (DC), (ii): B cell, (iii): both),
known as ligand for TLR9, to IgAN prone mice and analyzed disease phenotype of each group. After 8 times of the weekly
administration, every group showed deterioration of glomerular damage. However, CpG-A-group showed clear extension of
mesangial proliferative lesions with increase of serum IgA-IgG2a IC and its glomerular depositions, while CpG-B-group showed
extent of glomerular sclerotic lesions with increase of serum and glomerular IgA and M2 macrophage inﬁltration. Present results
indicate that mucosal TLR9 on B cells and DC may diﬀerently contribute to the progression of this disease via induction of
nephritogenic IgA or IgA-IgG IC, respectively. This picture is suggestive for the pathological diﬀerence between child and adult
IgAN.
1.Introduction
Although the deﬁnition of IgA nephropathy (IgAN) is
simple [1], the disease shows wide variation in clinical
course and pathological phenotypes, both of which occur
independent of disease duration after its onset. The clinical
and pathological manifestations of IgAN also vary between
adults and children [2–4]. The pathological factors that are
the main determinants for this heterogeneity have not been
elucidated to date.
Clinical evidence from kidney transplantation strongly
indicates that IgAN pathogenesis is primarily linked to ab-
normalities in the systemic IgA immune system, rather
than to intrinsic abnormalities in renal cells [5–8]. Previous
reports have demonstrated that mesangial and serum IgA1
show abnormal O-glycosylation in IgAN cases [9, 10]. In
this regard, the contribution of galactose-deﬁcient IgA1
(GdIgA1) and glycan-speciﬁc anti-IgA IgG antibodies has
recently been implicated in the pathogenesis of IgAN
[11–14]. However, the underlying mechanisms by which
these nephritogenic IgA and IgG immune complexes (IC)
are produced remain obscure.
Studies on bone marrow (BM) or BM transplantation
in IgAN [15–18] suggest that nephritogenic IgA is over-
produced in systemic immune sites, such as BM. There is
also clinical evidence that episodic macrohematuria coin-
c i d e sw i t hm u c o s a li n f e c t i o n s[ 19], abnormal responses to
mucosal vaccination [20, 21], and tonsillectomy in IgAN
patients with long-term renal survival [22]. These ﬁndings
indicate that dysregulation of the mucosal immune system
is involved in the pathogenesis of IgAN [23]. On the basis
of the ﬁndings of an elegant series of studies carried out in
the 1980s, van Es et al. hypothesized that a “mucosa-BM
axis” exists in IgAN. This axis was thought to be involved
in continual traﬃcking of cells between mucosal sites and
BM in the IgA immune system [24, 25]. Clinical and2 Clinical and Developmental Immunology
experimental studies in the last decade have revealed the
detailed mechanisms by which lymphocytes travel between
the mucosa and systemic lymphoid tissues. Although these
ﬁndings support the hypothesis proposed by van Es et al.,
the cell types involved and their contribution to the immune
system remain unclear [26].
Recently,wecarriedoutexperimentalandclinicalstudies
[27, 28] which demonstrated that toll-like receptor 9 (TLR9)
is a key participating molecule in innate and mucosal
immunity, and that it has a pathological role in both human
and murine IgAN. These studies also showed that the
activation of TLR9 on mucosal sites, particularly mucosal
sites in the upper respiratory tract, was important for the
progression of IgAN. These ﬁndings therefore provide clear
evidence that the cells responsible for expressing TLR9 may
be localized on mucosal sites, including the tonsils. TLR9 is
expressed mainly by B cells and dendritic cells (DCs) [29–
31], and as both these cells play key roles in innate/mucosal
immunity, it is possible that the activation of TLR9 in
the mucosa may be involved in the pathogenesis of IgAN.
However, the contribution of each cell to the pathogenesis
via TLR9 activation has not been examined. The innate
immunesystemofvertebratesisabletodistinguishself-DNA
from bacterial or other prokaryotic DNA. This is achieved
by detecting unmethylated CpG-oligonucleotides (ODNs),
in particular base contexts “CpG motifs,” via pattern recog-
nition receptors, such as TLR9 [32–35]. Diﬀerent CpG-
ODNs have been used to study cell regulation by TLR9 in
DC, and it has been shown that CpG-A-ODN induces large
amounts of IFN-α in plasmacytoid DC, CpG-B-ODN acts as
a potent stimulant of B cells, and CpG-C-ODN functions as
an activator of both B cells and DC [36–38]. However, the
detailed regulatory mechanisms in speciﬁc cell types has yet
to be established [39]. In the present study, we examined the
roleofTLR9oneachcelltypeinvolvedinIgANpathogenesis,
by administering cell-speciﬁc TLR9 ligands to a recently
established IgAN-prone mouse model [40, 41].
2.MaterialandMethods
2.1. Animals. The ddY mice (SLC Japan, Shizuoka, Japan)
were maintained in a speciﬁc pathogen-free room at the
animal facility of Juntendo University Faculty of Medicine
and provided with regular chow (MF; Oriented Yeast, Tokyo,
Japan). The original ddY mice were maintained as outbred
animals and were therefore genetically heterogeneous. How-
ever, we evaluated their renal histology by serial biopsies
and found that they could be classiﬁed into three groups on
the basis of their renal lesions. Approximately 35% of these
mice had glomerulonephritis with mesangial IgA deposition
before 20 weeks of age [42]. We deﬁned these mice as
early-onset mice and subsequently carried out inbreeding
of the group over 20 generations. The incidence rate of
IgAN onset in the IgAN-prone mice was almost 100%. We
used these IgAN-prone mice under speciﬁc pathogen-free
conditions, with age-matched BALB/c as controls (N =
3). The experimental protocol was approved by the Ethics
Review Committee for Animal Experimentation at Juntendo
University Faculty of Medicine.
2.2. Immunization with CpG-ODN. For assessment of the
exogenous pathogen-mediated immune response, three dif-
ferent types of CpG-ODN were administered nasally. The
administered CpG-ODN included three types, A, B, and C,
based on the type of eﬀector cell targeted. Type A activated
DC, type B activated B cells, and type C stimulated both
DC and B cells [36–38]. In the present study, ODN1585
(Invivogen, San Diego, California, USA), ODN1668, and
ODN2395 were used as types A, B, and C CpG-ODN,
respectively. Four-week old IgAN-prone ddY mice were
challenged nasally with 10μg of each CpG-ODN (N = 3)
at weekly intervals for eight consecutive weeks. We also
prepared ddY mice nasally challenged with CpG-ODN-
vehicle alone (endotoxin free water) as vehicle control (N =
3). For evaluation of renal damage, the same dose of CpG-
ODN was administered to age-matched BALB/c mice (N =
3). Blood and urine samples were collected before and
after each administration. After eight weeks from the ﬁrst
mucosal immunization, kidney samples were collected for
histopathological evaluation.
2.3. Histology and Immunohistochemistry. The kidney sam-
ples were ﬁxed in 10% neutral phosphate-buﬀered formalin,
embedded in paraﬃn, followed by the preparation of 2μm
thick sections. The sections were then stained with periodic
acid-Schiﬀ reagent or Azan for assessment of histological
changes by light microscopy. For immunohistochemical
analysis, snap-frozen 3μm thick renal sections were stained
with goat anti-mouse IgA antibody (Bethyl, Montgomery,
TX, USA) or rabbit anti-mouse IgG antibody (Rockland,
Philadelphia, Pennsylvania, USA). DyLight 488 conjugated
anti-goat IgG antibody (Rockland) or DyLight 649 con-
jugated anti-rabbit IgG antibody (Rockland) were used
as secondary antibodies. Frozen kidney sections ﬁxed in
acetone were stained with the following antibodies: type
I collagen (Abcam, Cambridge, UK), type IV collagen
(Abcam), α-smooth muscle actin (α-SMA; Dako, Glostrup,
Denmark), CD68 (AbD Serotec, Raleigh, USA), and CD204
(AbD Serotec). Horseradish peroxidase-labeled goat anti-
rat IgG antibody (Nichirei Bioscience, Tokyo, Japan) or
horseradish peroxidase-labeled goat anti-rabbit IgG anti-
body (Dako) were then applied as the secondary antibodies.
Bound antibodies were detected using an enhanced DAB
kit (Dako). Kidney specimens that contained more than 30
glomeruli were used for the histopathological analysis, with
the degree of ﬂuorescence intensity being evaluated using
an Olympus FV1000 system (Olympus, Tokyo, Japan) and
Photoshop Element 2.0 (Abode, San Jose, USA). The degree
ofmesangiummatrixexpansionwasevaluatedusingtheCarl
Zeiss Axioskop2 plus and Carl Zeiss KS 400 3.0 systems (Carl
Zeiss, Oberkochen, Germany).
2.4. Serum and Urinary Analyses. Blood samples were ob-
tained from the orbital venous plexus using capillary tubes.
Serum IgA and IgG levels were measured using an ELISA
kit (IgA or IgG Quantitation, Bethyl). Serum IgA-IgG2a
IC levels were determined by sandwich ELISA, as reported
previously [43]. Urinary albumin was also measured usingClinical and Developmental Immunology 3
an ELISA kit (Albuwell, Exocell, Philadelphia, Pennsylvania,
USA).
2.5. Statistical Analysis. The correlation between diﬀerent
parameters in the groups was analyzed by ANOVA. Data are
expressed as mean ± SD or median values. P<. 05 was
considered statistically signiﬁcant. All the statistical analyses
were performed using the Windows version of StatView 5.0
software (Abacus Concepts, Berkeley, CA, USA).
3. Results
Each CpG-ODN exacerbated pathologically diﬀerent glom-
erular lesions in murine IgAN models.
As reported previously [44], CpG-ODN administration
aggravated urinary albumin and glomerular injury in IgAN-
prone mice, in comparison with the aggravation in the
ddY vehicle control group (Figure 1). On the other hand,
CpG-ODN administration caused no elevation in urinary
albumin excretion and/or glomerular damage in normal
Balb/c mice (data not shown). However, each dose of
CpG-ODN induced a diﬀerent amplitude of aggravation in
urinary albumin excretion (Figure 1(a)), and also induced
diﬀerent types of pathological lesions (Figure 1(b)). CpG-A-
ODN administration induced more proliferative glomerular
lesions and higher urinary albumin excretion, while CpG-
B-ODN induced greater ECM expansion in glomeruli, as
shown by staining with Azan and collagen types I and IV
(Figure 1(b)).CpG-C-ODNadministrationinducedamixed
type of damage. Semiquantiﬁcation of the staining patterns
by counting cell numbers and calculating the ratio of ECM
area in the glomeruli conﬁrmed the presence of signiﬁcant
diﬀerences in the pathological lesions (Figure 1(c)). Activa-
tion of TLR9 on DC and B cells in mucosal sites caused
diﬀerent aggravation of glomerular damage in murine IgAN,
a ﬁnding that highlighted the diﬀerent roles of these cells in
the disorder.
Each CpG-ODN may have a diﬀerent capacity to induce
nephritogenic IgA and IgA-IgG2a IC.
We have previously reported that this model of IgAN-
prone mice have codeposition of IgA and IgG in their
glomeruli, similar to that seen in human IgAN [42], and
that the severity of this disease correlates closely with
serum IgG2a levels [43]. On the basis of these ﬁndings we
examined the glomerular deposition of IgA and IgG and
the serum levels of IgA and IgA-IgG2a IC. The ﬂuorescence
intensity of glomerular IgA in the CpG-B-ODN group was
signiﬁcantly higher than that in the CpG-A-ODN group
(Figure 2(a)). In contrast, the CpG-A-ODN group showed a
signiﬁcantly higher intensity of IgG than the CpG-B-ODN
group (Figure 2(b)). The CpG-B-ODN and CpG-A-ODN
groups also showed consistently higher serum levels of IgA
and IgA-IgG2a IC, respectively (Figure 2(c)). The ratio of
pre- and postadministration serum IgA levels was higher in
the CpG-B-ODN group until 8 weeks, while the ratio of
the pre- and postadministration serum IgA-IgG2a IC levels
during the early phase were higher in the CpG-A-ODN and
CpG-C-ODN groups (Figure 2(d)).
Polarization of glomerular macrophages diﬀers in each
CpG-ODN group.
Previous studies have suggested that polarization of
glomerular macrophages may contribute to the patterns
of glomerular damage in IC-mediated glomerulonephri-
tis, including IgAN [45–47]. Accordingly, we examined
the expressions of CD68 (pan macrophages) and CD204
(M2 macrophages) in the glomerular macrophages (Figures
3(a) and 3(b)). As shown in Figure 3(b), the number of
CD204+ cells increased in the CpG-B-ODN group. The
CD204+/CD68+ ratio in glomeruli was greater than 80% in
the CpG-B-ODN group and less than 50% in the CpG-A-
ODN group. This ﬁnding suggests that macrophages in the
CpG-B-ODN group were polarized mainly to M2.
4. Discussion
The ﬁndings of the present study revealed that CpG-A-ODN
and CpG-B-ODN exacerbated diﬀerent types of glomerular
damage.Thisdamageconsistedmainlyofmesangialprolifer-
ation or ECM expansion in association with serum elevation
of IgA-IgG2a IC and enhanced glomerular deposition of
IgA. The study therefore provides further conﬁrmation that
activationofmucosalTLR9byCpG-ODNaggravatesmurine
IgAN [40] and strongly indicates that the activation of TLR9
on DC and B cells may aﬀord diﬀering contribution to the
disease process.
It is widely accepted that mesangial IgA is predominantly
IgA1 that displays abnormal O-glycosylation [9, 10]i n
human IgAN. This indicates that aberrantly glycosylated IgA
has a pathological role in human IgAN [48, 49]. It is also
well known that tonsillar B lymphocytes in IgAN patients
produceunder-O-glycosylatedIgA1suchasGdIgA1[50–52].
IgAN may be associated with a maldistribution of nephri-
togenic IgA secreting B cells from mucosal to systemic sites
includingbonemarrows[17,23,53].SinceTLRdirectlycon-
tribute to homing process of lymphocytes and DC [54–56],
mucosal/tonsillarBcellssecretingtheaberrantlyglycosylated
IgA may further disseminate to other lymphoid tissues after
TLR activation. In addition, these tonsillar B cells show
downregulation of β 1,3-galactosyltransferase activity, a key
enzyme that catalyzes O-galactosylation at the hinge region
of IgA1 [57]. Further, there is evidence suggesting that
aberrantly glycosylated IgA is involved in the pathogenesis
of murine IgAN [58, 59]. Humans have two isotypes of
IgA, IgA1, and IgA2. Speciﬁcally, IgA1 produces longer hinge
lesions with O-glycosylation sites, whereas murine IgA does
not [49, 60]. This implies that GdIgA1 may not be involved
in the pathogenesis of murine IgAN. However, recent
evidence suggests that aberrant glycosylation of N-glycans
regulated by β 1,4-galactosyltransferase are involved in the
pathogenesis of murine IgAN [58, 59]. It is therefore possible
that aberrant modiﬁcations of carbohydrates in serum IgA
are involved in the development of both human and murine
IgAN, independent of whether or not the carbohydrates
are O- or N-glycans. The IgAN-prone mice used in the
present study were originally established from ddY mice
[42] which produce nephritogenic aberrantly glycosylated4 Clinical and Developmental Immunology
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Figure 1: The disease course in each CpG-ODN group. (a) Urinary albumin in each group. Arrows indicate administration of each CpG-
ODN agent. Urine samples were collected before and after administration. (b) Glomerular pathological changes at eight weeks. Glomerular
damage in each CpG-ODN and vehicle control group were evaluated by PAS and Azan staining, and immunohistochemical analysis of α-
SMA, type I collagen (Col. I), and type IV collagen (Col. IV). (c) Evaluation of cell proliferation and extracellular matrix (ECM) expansion
in the glomeruli of each CpG-ODN group. Cell proliferation was evaluated by counting the average cell number in each glomerulus. ECM
expansion was evaluated by the percentage of blue areas in each glomerulus stained by AZAN. In both experiments, more than 30 glomeruli
were evaluated in each mouse. Magniﬁcation in (b): 400X.Clinical and Developmental Immunology 5
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Figure 2: Glomerular deposition and serum levels of IgA, IgG, and IgA/IgG immune complexes (IC). (a) Immunoﬂuorescence staining of
IgA and IgG in the glomeruli of each CpG-ODN group. (b) Fluorescence intensity of IgA and IgG in glomeruli. The ﬂuorescence intensity of
each immunoglobulin was evaluated in more than 30 glomeruli. (c) Serum IgA (mg/dL) and (d) IgA-IgG2a IC (OD). The ratios of pre/post
administration for IgA and IgA-IgG2a IC were also evaluated. Magniﬁcation in (a): 400X.
IgA [59]. Our recent study also indicated that B cells are
responsibleformurineIgANproducingnephritogenicIgAin
T-cell-independent (unpublished data) and germinal center-
independent manners [61]. In addition to exacerbating
murine IgAN by increasing serum IgA levels and glomerular
deposition of CpG-B-ODN, mucosal B cells responsible
for these actions may also cause increased production of
aberrantly glycosylated nephritogenic IgA via activation of
their own TLR9.
It is now apparent that serum levels of GdIgA1 are
often elevated in IgAN patients [11–13, 62]. Gharavi et al.
recently reported that GdIgA1 levels were increased in
78% of patients with sporadic IgAN and in 25% of their
blood relatives, although the majority of relatives with
abnormal IgA1 glycoforms were asymptomatic [63]. This
ﬁnding suggests that additional cofactors are required for
development ofIgANincertaincases.Inarecentpublication
Suzuki and coworkers described the characteristics of IgG
autoantibodies to abnormally glycosylated IgA1 secreted by
immobilized B cells derived from patients with sporadic
IgAN [13]. The serum levels of these IgG autoantibodies
correlated closely with the degree of proteinuria, suggesting
that IC formation of aberrantly glycosylated IgA and glycan-
speciﬁc IgG antibodies may be an additional cofactor
required for full development of the disease [53, 64]. In
this regard, it is noteworthy that the serum levels of IgA-
IgG2a IC, but not of IgA, were shown to correlate closely
with the severity of glomerular lesions in IgAN-prone mice
[43]. In addition to the aberrant glycosylation of IgA [58,
59], similar mechanisms about immune complex formation
may underlie the progression of both human [13]a n d
murine [43] IgAN. Therefore, disease aggravation caused by
elevation of serum IgA-IgG2a IC levels and the increased
codeposition of IgA and IgG observed in the CpG-A-ODN
group, suggest that mucosal TLR9 activation on DC may be
involved in the production of glycan-speciﬁc autoantibodies.
Recent clinical and experimental papers have indicated that
abnormal somatic mutations in the germinal center may
contribute to the production of autoantibodies in autoim-
mune diseases [56, 65]. These papers also suggested that
DC-B-cell interactions may be involved in such T-cell-in-
dependent antibody production, presumably including pol-
yreactive and autoreactive antibodies. Therefore, DC-B-cell
interactions should be examined carefully in future studies
investigating the pathogenesis of IgAN.
The present models treated with each CpG-ODN high-
lighted the fact that the two major pathological characteris-
tics of IgAN, mesangial proliferation and ECM expansion,
may combine to result in an increase in serum levels of
IgA-IgG2a IC and IgA in glomeruli. It is known that heat-
aggregated IgA has strong capacity to induce mesangial pro-
liferation, and ECM expansion via cytokine production such
as IL-6 and TGF-β [66, 67]. However, recent papers showed
that human aberrantly glycosylated IgA has no strong ca-
pacity for mesangial proliferation, while IgG-conatining IgA
IC shows strong capacity for the proliferation [68, 69].
Therefore, same mechanisms for mesangial activation by
IgA or IgA-IgG IC may underlie murine IgAN. Interestingly,
these two characteristics represent the typical pathological
manifestations of child and adult IgAN. Further, it is known
that mesangial enlargement in pediatric IgAN is due mainly
to mesangial hypercellularity rather than to increased pro-
duction of matrix, whereas mesangial matrix expansion is
the predominant ﬁnding in adult IgAN [2–4]. This tendency
has also been observed in new-onset pediatric and adult
IgAN [2]. Although there is still no clear explanation forClinical and Developmental Immunology 7
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Figure 3: Phenotype of inﬁltrated glomerular macrophages in each CpG-ODN group. The phenotypes of inﬁltrated macrophages were
evaluated immunohistologically using anti-CD68+ (pan macrophage) and anti-CD204+ (M2 macrophage) antibodies (a). In addition, the
average number of each inﬁltrated glomerular macrophage and the phenotypic ratio were also evaluated (b). More than 30 glomeruli were
evaluated in each stained section from each animal. Magniﬁcation in (a): 400X.8 Clinical and Developmental Immunology
this mechanism, the roles of macrophage subsets have
been considered [70]. Macrophages have been implicated
as mediators of renal injury in glomerulonephritis and
the degree of their accumulation is predictive of disease
progressioninIgAN[70].Bloodmonocytesdiﬀerentiateinto
macrophages, the phenotype of which is dependent upon
the local microenvironment encountered. These polarized
macrophages have been classiﬁed into two broad groups;
classically activated (M1) or alternatively activated (M2)
macrophages [46]. In general, classically activated M1
macrophages are tissue injury type macrophages involved
in the expansion of inﬂammation, while M2 macrophages
have immunoregulatory and immunosuppressive functions
[45, 46]. While some studies have argued a tissue reparative
role for M2 macrophages, other studies have suggested that
some subtypes of alternatively activated M2 macrophages
have a proﬁbrotic phenotype [45, 47, 71]. Indeed, M1
macrophages express CCL15, CCL20, and CXCL9-11 which
are upregulated by acute inﬂammatory cytokines such as
IFNγ [72, 73]. On the other hand, CCL17, CCL18, and
DCIR on M2 macrophages are mainly regulated by anti-
inﬂammatory Th2 cytokines, such as IL-4 [72, 73]. In
addition, M1 macrophages strongly express FcγRI and III
known as inﬂammatory FcγRs, while M2 macrophages
mainly express FcγRII known as inhibitory FcγR[ 72, 73].
Therefore, increase of IgG-containing IgA IC deposition in
glomerulus may inﬂuence glomerular cytokine condition
and thus subsequent polar form of macrophages, partly via
chemokine receptor expressions.
An important ﬁnding in the present study was that the
majority of glomerular macrophages in the CpG-B-ODN
group were CD204+ M2 macrophages and were associ-
ated with ECM expansion. As M2 or M2-like phenotypic
macrophages are increased in adult IgAN [2, 47], it needs
to be examined whether the mechanism by which an acute
increase in deposition of aberrantly glycosylated IgA in
glomeruli induces the activation of M2 macrophages and
subsequent ﬁbrotic changes. On the other hand, we found
the ratio of M1/M2 macrophages was increased in the
CpG-A-ODN group, suggesting that codeposition of IgG
delivered by IgA-IgG2a IC may establish an inﬂammatory
milieu for M1 polarization and subsequent further localized
elevation of inﬂammatory cytokines that induce mesangial
proliferation, such as IL-6 [66, 74–76].
5. Conclusion
The present study demonstrated that mucosal activation of
TLR9 on B cells and DC had diﬀerent contributions to the
progression of murine IgAN, presumably via formation of
nephritogenic IgA and IgA-IgG IC, respectively. Although
further study is necessary to determine how IgA and IC
induce pathological manifestation via assembly of M1/M2
macrophage,thepresentresultsmayprovideimportantclues
for future radical treatment modalities for IgAN.
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